Login to Your Account

Earnings Roundup

Wednesday, February 29, 2012
• Human Genome Sciences Inc., of Rockville, Md., reported fourth-quarter 2011 revenues of $45.5 million, with $25.7 million coming from sales of lupus drug Benlysta (belimumab), in line with what the firm had pre-announced last month. Net loss for the quarter totaled $81 million, or 41 cents per share, narrower than the consensus estimates of a loss of 43 cents per share.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription